Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b

详细信息	查看全文 | 推荐本文 |

• 作者：Raquel Muñ ; oz ; Yol ; a Arias ; José ; M. Ferreras ; Marí ; a A. Rojo ; Manuel J. Gayoso ; Mercedes Nocito ; Jorge Benitez ; Pilar Jimé ; nez ; Carmelo Bernabé ; u ; Tomas Girbé ; s
• 关键词：Nigrin b ; Endoglin ; Anti-endoglin antibody ; Transfectant hCD105 cells ; Anti-tumour therapy
• 刊名：Cancer Letters
• 出版年：2007
• 期刊代码：44_03043835
• 类别：med
• 出版时间：18 October 2007
• 卷：256
• 期：1
• 页码：73-80
• 文件大小：345 K

摘要

Targeting tumour neovasculature using antibodies to the endothelial receptor CD105 (endoglin), is a potentially useful approach for anti-tumour therapy. We report on the preparation and the cytotoxicity of a novel immunotoxin consisting in the non-toxic type 2 ribosome-inactivating protein (RIP) nigrin b linked to the monoclonal anti-human CD105 (hCD105) antibody 44G4. The immunotoxin kills specifically mouse fibroblasts expressing the biomarker CD105 (L929-hCD105+ cells) with an IC₅₀ value of 6 × 10⁻¹⁰ M while nigrin b does it at 2.4 × 10⁻⁷ M. Immunofluorescence analysis indicated that the immunotoxin accumulates in a perinuclear region. In contrast, 44G4 showed a specific localization on the cell surface.